Physician Views: Will generic Copaxone disrupt the US multiple sclerosis market?

The FDA approved Mylan's generic version of Copaxone 40mg last week, exposing Teva's flagship multiple sclerosis franchise to an earlier-than-expected risk of sales erosion in the US market – ViewPoints: A fatal blow to Teva's Copaxone empire?

Payers will embrace generic availability as a means to drive down costs, but some MS key opinion leaders (KOLs) are cautious towards future use of generic products given Copaxone's complexity. To get a better understanding, therefore, of how generic Copaxone 40mg may be used, we are snap-polling US neurologists with the following series of questions…

The FDA has approved the first generic version of Copaxone (glatiramer acetate) 40mg (3 times-a-week dosing); it is manufactured by Mylan. How comfortable are you with the idea of prescribing generic Copaxone 40mg?

Very uncomfortable

Moderately uncomfortable

Slightly uncomfortable

Neither comfortable or uncomfortable

Slightly comfortable

Moderately comfortable

Very comfortable

If payers dictate that you must prescribe generic Copaxone 40mg before branded Copaxone will you…

Support it – Cost savings are beneficial for healthcare system

Accept it – I would rather use branded version, but the generic is FDA approved/cost savings are beneficial for healthcare system

Question it – I would be worried about possible clinical discrepancies irrespective of regulatory assessment; will be situations where I insist on using branded originator

Reject it – I will actively seek to reject use of generic in most cases

Reject it outright – I will refuse to use the generic in all cases

What about if payers were to mandate use of generic Copaxone 40mg for new patients before they can progress to treatments with other mechanisms of action?

Support it

Accept it

Question it

Reject it

Reject it outright

Assuming the price of Copaxone 40mg falls significantly as a result of generic launches, would you expect your utilisation of this treatment (glatiramer acetate; either in branded or generic form) as first-line therapy to increase?


Yes – slightly

Yes – moderately

Yes – significantly

Yes – very significantly

Apart from branded Copaxone, what other branded therapy would you expect to use less frequently if your use of glatiramer acetate in first-line patients was to increase due to lower cost?













Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at

To read more Physician Views articles, click here.